NUREMBERG, Germany, May 16, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that Vical is presenting on the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine, and ...
SAN DIEGO, Sept. 13, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its ...
Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child 14.12.2021 / 07:00 The issuer is solely ...
In a recent article published in the journal JAMA Network, researchers performed a randomized clinical trial (RCT) to demonstrate the noninferiority of letermovir vs. valganciclovir for prophylaxis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback